Bayer Aktiengesellschaft (BAYRY) News
Follow Bayer Aktiengesellschaft (BAYRY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bayer Says Nubeqa Cut Metastasis or Death Risk 58% in Phase III Trial
Bayer reported interim Phase III DASL-HiCaP results for Nubeqa (darolutamide) plus androgen deprivation therapy.
EQUITY | Oct 26, 2026, 08:38 AM UTC
L
Bayer Affirms FY2026 currency-adjusted Adj EPS Guidance of $1.20-$1.35 vs $1.25 Est; Affirms FY2026 currency-adjusted Sales Guidance of $52.
Bayer (OTC: BAYRY ) affirms FY2026 currency-adjusted Adj EPS guidance from $1.20-$1.35 to $1.20-$1.35 vs $1.25 analyst estimate. Affirms FY2026 currency-adjusted sales outlook from $52.109 billion-$54.451 billion to $52.
EARNINGS | Aug 04, 2026, 07:58 AM UTC
L
Bayer, Henry Ford Health partner to expand access to clinical trials
Bayer, Henry Ford Health partner to expand access to clinical trials
EQUITY | Jul 17, 2026, 12:36 PM UTC
H
Bayer Wins Roundup Case
Bayer wins Supreme Court case limiting thousands of state lawsuits over claims that Roundup's active ingredient causes cancer
EQUITY | Jun 26, 2026, 08:12 AM UTC
H
Bayer Wins Roundup Ruling
US Supreme Court rules in favor of Bayer to limit state-court lawsuits claiming Roundup causes cancer
EQUITY | Jun 25, 2026, 02:04 PM UTC